Evidence map›Paper›PMID 26185368›Full record

ReviewWorld journal of gastroenterology2015

Multimodal treatment of gastric cancer in the west: Where are we going?

Daniele Marrelli, Karol Polom, Giovanni de Manzoni, Paolo Morgagni, Gian Luca Baiocchi, Franco Roviello

Abstract readEditorialReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniele MarrelliDaniele Marrelli, Karol Polom, Franco Roviello, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
Karol PolomDaniele Marrelli, Karol Polom, Franco Roviello, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
Giovanni de ManzoniDaniele Marrelli, Karol Polom, Franco Roviello, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
Paolo MorgagniDaniele Marrelli, Karol Polom, Franco Roviello, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
Gian Luca BaiocchiDaniele Marrelli, Karol Polom, Franco Roviello, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.
Franco RovielloDaniele Marrelli, Karol Polom, Franco Roviello, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of gastric cancer (GC) is decreasing worldwide, especially for intestinal histotype of the distal third of the stomach. On the contrary, proximal location and diffuse Lauren histotype have been reported to be generally stable over time. In the west, no clear improvement in long-term results was observed in clinical and population-based studies. Results of treatment in these neoplasms are strictly dependent on tumor stage. Adequate surgery and extended lymphadenectomy are associated with good long-term outcome in early-stage cancer; however, results are still unsatisfactory for advanced stages (III and IV), for which additional treatments could provide a survival benefit. This implies a tailored approach to GC. The aim of this review was to summarize the main multimodal treatment options in advanced resectable GC. Perioperative or postoperative treatments, including chemotherapy, chemoradiotherapy, targeted therapies, and hyperthermic intraperitoneal chemotherapy have been reviewed, and the main ongoing and completed trials have been analyzed. An original tailored multimodal approach to non-cardia GC has been also proposed.

Indexed as

GastrectomyChemoradiotherapy, AdjuvantChemotherapy, AdjuvantHumansIncidenceLymph Node ExcisionMolecular Targeted TherapyNeoadjuvant TherapyNeoplasm MetastasisNeoplasm StagingPatient SelectionRadiotherapy, AdjuvantRisk FactorsStomach NeoplasmsTime FactorsTreatment OutcomeChemotherapyEpidemiologyGastric cancerHyperthermic intraperitoneal chemotherapyRadiotherapyTargeted therapy

Identifiers

PMID26185368
PMCPMC4499339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.